Chia‐Chi Lin

3.1k total citations
115 papers, 2.3k citations indexed

About

Chia‐Chi Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chia‐Chi Lin has authored 115 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Chia‐Chi Lin's work include Lung Cancer Treatments and Mutations (42 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Lung Cancer Research Studies (21 papers). Chia‐Chi Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Lung Cancer Research Studies (21 papers). Chia‐Chi Lin collaborates with scholars based in Taiwan, United States and South Korea. Chia‐Chi Lin's co-authors include James Chih‐Hsin Yang, Jih‐Hsiang Lee, Bin-Chi Liao, Chih‐Hung Hsu, Jin‐Yuan Shih, Ann‐Lii Cheng, Chong‐Jen Yu, Chao‐Chi Ho, Todd M. Bauer and Benjamin Solomon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Chia‐Chi Lin

111 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chia‐Chi Lin Taiwan	28	1.3k	1.3k	653	324	306	115	2.3k
G. Deplanque France	23	1.3k 1.0×	812 0.6×	633 1.0×	542 1.7×	225 0.7×	77	2.3k
Mizutomo Azuma Japan	25	927 0.7×	1.2k 1.0×	420 0.6×	241 0.7×	810 2.6×	91	2.2k
Giuseppe Badalamenti Italy	25	1.0k 0.8×	764 0.6×	621 1.0×	553 1.7×	441 1.4×	144	2.3k
Sebastiano Buti Italy	26	1.1k 0.9×	1.2k 1.0×	690 1.1×	485 1.5×	369 1.2×	210	2.2k
Takashi Karashima Japan	24	770 0.6×	790 0.6×	1.1k 1.6×	547 1.7×	558 1.8×	119	2.3k
Xue Hou China	26	1.3k 1.0×	1.0k 0.8×	376 0.6×	317 1.0×	387 1.3×	104	2.1k
Feng Du China	22	1.3k 1.0×	883 0.7×	645 1.0×	503 1.6×	470 1.5×	75	2.2k
Shinichi Tsutsui Japan	23	982 0.8×	565 0.5×	651 1.0×	408 1.3×	549 1.8×	96	2.0k
In‐Gu Do South Korea	31	1.0k 0.8×	691 0.6×	1.1k 1.6×	516 1.6×	377 1.2×	97	2.5k
Hao Long China	27	853 0.7×	1.1k 0.8×	913 1.4×	565 1.7×	554 1.8×	177	2.6k

Countries citing papers authored by Chia‐Chi Lin

Since Specialization

Citations

This map shows the geographic impact of Chia‐Chi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia‐Chi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia‐Chi Lin more than expected).

Fields of papers citing papers by Chia‐Chi Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chia‐Chi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia‐Chi Lin. The network helps show where Chia‐Chi Lin may publish in the future.

Co-authorship network of co-authors of Chia‐Chi Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Chia‐Chi Lin. A scholar is included among the top collaborators of Chia‐Chi Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chia‐Chi Lin. Chia‐Chi Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Chia‐Chi & Chien‐Sheng Chen. (2025). Bacterial proteome microarray technology in biomedical research. Trends in biotechnology. 43(6). 1317–1327.

Desai, Jayesh, Andrew J. Wagner, Marilena Cesari, et al.. (2024). A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib. Cancer. 131(1). e35634–e35634. 5 indexed citations

Kim, Tae Min, Nuttapong Ngamphaiboon, Ki Hyeong Lee, et al.. (2023). 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor. SHILAP Revista de lepidopterología. A1808–A1808. 1 indexed citations

Liang, Cher‐Wei, et al.. (2023). Abstract 2211: The prognostic role of tertiary lymphoid structure (TLS) in locally advanced esophageal squamous cell carcinoma (ESCC). Cancer Research. 83(7_Supplement). 2211–2211. 1 indexed citations

Chen, Shih-Cheng, et al.. (2023). Optimization of 5′UTR to evade SARS-CoV-2 Nonstructural protein 1-directed inhibition of protein synthesis in cells. Applied Microbiology and Biotechnology. 107(7-8). 2451–2468. 4 indexed citations

Lin, Chia‐Chi, et al.. (2022). Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma. Esophagus. 19(4). 693–701.

Hsu, Chia‐Lang, Yenlin Huang, Chia‐Chi Lin, et al.. (2022). B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma. Frontiers in Oncology. 12. 879398–879398. 7 indexed citations

Soo, Ross A., Eng Huat Tan, Hidetoshi Hayashi, et al.. (2022). Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer. 169. 67–76. 13 indexed citations

Lin, Chia‐Chi, Toshihiko Doi, Kei Muro, et al.. (2021). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted Oncology. 16(4). 447–459. 22 indexed citations

10.

Lin, Chia‐Chi. (2021). Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors. SHILAP Revista de lepidopterología. 4(2). 105–114. 41 indexed citations

11.

Lin, Chen‐Yuan, et al.. (2021). Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites. Oncology. 99(10). 652–658. 1 indexed citations

12.

Strickler, John H., Patricia LoRusso, Ravi Salgia, et al.. (2020). Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 19(5). 1210–1217. 21 indexed citations

13.

Drakaki, Alexandra, Michiel S. van der Heijden, Daniel P. Petrylak, et al.. (2019). Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer. 6(1). 43–52. 2 indexed citations

14.

Lin, Chia‐Chi, Yun‐Chun Wu, Jason Chia‐Hsien Cheng, et al.. (2018). Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association. 118(6). 1024–1030. 4 indexed citations

15.

Huang, Pei‐Ming, et al.. (2017). Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?. Digestive Surgery. 35(2). 104–110. 3 indexed citations

16.

Park, Keunchil, Byoung Chul Cho, Ki Hyeong Lee, et al.. (2017). P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results. Journal of Thoracic Oncology. 12(1). S1187–S1188. 1 indexed citations

17.

Hsiue, Emily Han-Chung, Jih‐Hsiang Lee, Chia‐Chi Lin, & James Chih‐Hsin Yang. (2016). Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Review of Molecular Diagnostics. 16(12). 1251–1257. 18 indexed citations

18.

Liao, Bin-Chi, Jih‐Hsiang Lee, Chia‐Chi Lin, et al.. (2015). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology. 10(12). 1754–1761. 138 indexed citations

19.

Lin, Chia‐Chi, Min‐Shu Hsieh, Chin‐Hao Chang, et al.. (2015). Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology. 10(10). 1481–1489. 17 indexed citations

20.

Mao, Hui‐Fen, et al.. (2010). Cross-cultural adaptation and validation of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0): the development of the Taiwanese version. Clinical Rehabilitation. 24(5). 412–421. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact